|NASDAQ: CLSD||Healthcare / Biotechnology / USA|
|0.9900||-0.0300||-2.94%||Vol 36.63K||1Y Perf -57.68%|
|Mar 24th, 2023 11:28 DELAYED|
|-0.01 -0.97%||- -|
|Target Price||6.25||Analyst Rating||Strong Buy 1.20|
|Potential %||531.31||Finscreener Ranking||★★★★+ 56.25|
|Insiders Trans % 3/6/12 mo.||-/-/-75||Value Ranking||★★★+ 52.88|
|Insiders Value % 3/6/12 mo.||-/-/-77||Growth Ranking||★★★★+ 62.89|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-87||Income Ranking||— -|
|Price Range Ratio 52W %||3.57||Earnings Rating||Neutral|
|Market Cap||60.75M||Earnings Date||10th May 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||10th May 2023|
|Estimated EPS Next Report||-0.14|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||110.22K|
|Avg. Monthly Volume||161.06K|
|Avg. Quarterly Volume||213.69K|
Clearside Biomedical Inc. (NASDAQ: CLSD) stock closed at 1.02 per share at the end of the most recent trading day (a 0.99% change compared to the prior day closing price) with a volume of 68.34K shares and market capitalization of 60.75M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 33 people. Clearside Biomedical Inc. CEO is George Lasezkay.
The one-year performance of Clearside Biomedical Inc. stock is -57.68%, while year-to-date (YTD) performance is -8.93%. CLSD stock has a five-year performance of -91.32%. Its 52-week range is between 0.93 and 2.61, which gives CLSD stock a 52-week price range ratio of 3.57%
Clearside Biomedical Inc. currently has a PE ratio of -27.30, a price-to-book (PB) ratio of 5.32, a price-to-sale (PS) ratio of 97.20, a price to cashflow ratio of 399.40, a PEG ratio of 2.32, a ROA of -11.60%, a ROC of -24.36% and a ROE of -27.18%. The company’s profit margin is -26.16%, its EBITDA margin is -15.40%, and its revenue ttm is $997.00 Thousand , which makes it $0.02 revenue per share.
Of the last four earnings reports from Clearside Biomedical Inc., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.14 for the next earnings report. Clearside Biomedical Inc.’s next earnings report date is 10th May 2023.
The consensus rating of Wall Street analysts for Clearside Biomedical Inc. is Strong Buy (1.2), with a target price of $6.25, which is +531.31% compared to the current price. The earnings rating for Clearside Biomedical Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Clearside Biomedical Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Clearside Biomedical Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 12.57, ATR14 : 0.10, CCI20 : -79.57, Chaikin Money Flow : -0.40, MACD : -0.09, Money Flow Index : 19.03, ROC : -20.31, RSI : 37.83, STOCH (14,3) : 22.50, STOCH RSI : 1.00, UO : 38.13, Williams %R : -77.50), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Clearside Biomedical Inc. in the last 12-months were: Charles A. Deignan (Option Excercise at a value of $9 454), Clay B. Thorp (Buy at a value of $14 266), Nancy J. Hutson (Buy at a value of $39 900), Thomas Ciulla (Sold 2 170 shares of value $3 515 )
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Strong Buy||Strong Buy||Strong Buy|
Clearside Biomedical Inc is the United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye. The product candidates of the company focus on a disease affecting the retina and aim to restore or improve visual function primarily by reducing the macular edema associated with several diseases affecting vision.
CEO: George Lasezkay
Telephone: +1 678 270-3631
Address: 900 North Point Parkway, Alpharetta 30005, GA, US
Number of employees: 33
Fri, 10 Mar 2023 12:30 GMT Analysts Top Healthcare Picks: Clearside Biomedical (CLSD), Pliant Therapeutics (PLRX)- TipRanks. All rights reserved.
Fri, 10 Mar 2023 12:20 GMT Analysts Offer Insights on Healthcare Companies: DarioHealth (DRIO), Clearside Biomedical (CLSD) and Homology Medicines (FIXX)- TipRanks. All rights reserved.
Fri, 10 Mar 2023 05:30 GMT Analysts Offer Insights on Healthcare Companies: Clearside Biomedical (CLSD) and Applied Molecular Transport (AMTI)- TipRanks. All rights reserved.
Wed, 15 Feb 2023 12:10 GMT Analysts Are Bullish on Top Healthcare Stocks: Clearside Biomedical (CLSD), CSL (CMXHF)- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.